Viatris (VTRS) Competitors

Viatris (NASDAQ:VTRS) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.

Is VTRS or TAK more profitable?

Takeda Pharmaceutical has a net margin of 6.49% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-5.87%	16.46%	7.09%
Takeda Pharmaceutical	6.49%	10.00%	4.78%

Which has preferable earnings & valuation, VTRS or TAK?

Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$15.05B	0.97	$54.70M	-$0.74	-16.59
Takeda Pharmaceutical	$4.55T	0.01	$994.06M	$0.58	22.86

Which has more volatility and risk, VTRS or TAK?

Viatris has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Do analysts rate VTRS or TAK?

Viatris presently has a consensus target price of $13.67, suggesting a potential upside of 11.29%. Given Viatris' stronger consensus rating and higher probable upside, equities research analysts clearly believe Viatris is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals & insiders hold more shares of VTRS or TAK?

79.9% of Viatris shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.1% of Viatris shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community favor VTRS or TAK?

Takeda Pharmaceutical received 78 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 56.82% of users gave Takeda Pharmaceutical an outperform vote while only 35.48% of users gave Viatris an outperform vote.

Company	Underperform	Outperform
Viatris	Outperform Votes 22 35.48%	Underperform Votes 40 64.52%
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%

Is VTRS or TAK a better dividend stock?

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 3.9%. Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 4.0%. Viatris pays out -64.9% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 91.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Does the media prefer VTRS or TAK?

In the previous week, Viatris had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 2 mentions for Viatris and 1 mentions for Takeda Pharmaceutical. Viatris' average media sentiment score of 0.00 beat Takeda Pharmaceutical's score of -0.03 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Viatris beats Takeda Pharmaceutical on 12 of the 20 factors compared between the two stocks.